Abstract
Therapy related Acute Myeloid Leukemia/Myelodysplastic syndrome (t-AML/MDS) occur due to the direct mutational events of the chemotherapeutic agents and radiotherapy. The disease latency, mutational events and prognosis vary with the type of chemotherapeutic agent. Therapy related Acute Myeloid Leukemia occurring with DNA topoisomerase II inhibitors have a shorter latency period and poor prognosis than anthracyclin based regimens. We report a case of a 9 year old boy who developed t-AML with mixed-lineage-leukemia gene translocation within a year of high dose chemotherapy for stage 4 neuroblastoma. He had residual mass of neuroblastoma in the abdomen and bone marrow. The patient expired within 2 weeks of induction chemotherapy.
References
Bown N (2001) Neuroblastoma tumour genetics: clinical and biological aspects. J Clin Pathol 54:897–910
Dondon MG (2003) Long-term risk of second malignant neoplasms after neuroblastoma in childhood: role of treatment. Int J Cancer 107:791–796
Godley LA, Larson RA (2008) Therapy-related myeloid leukemia. Semin Oncol 35(4):418–429
Tamai H, Inokuchiv K (2010) 11q23/MLL acute leukemia : update of clinical aspects. J Clin Exp Hematopathol 50:91–98
Santos-Machado TM, Zerbini MC, Cristofani LM, Azevedo PM, Almeida MT et al (2001) Simultaneous occurrence of advanced neuroblastoma and acute myeloid leukemia. Pediatr Hematol Oncol 18:129–135
Pedram M, Vafaie M, Jaseb K, Fekri K, Haghi S (2011) Simultaneous occurrence of advanced neuroblastoma and acute lymphoblastic leukemia: a case report. Middle East J Cancer 2(1):33–36
Conflict of Interest
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sylvia, M.T., Rani, J., Basu, D. et al. Concurrent Presentation of Therapy Related Acute Myeloid Leukemia in a Case of Neuroblastoma. Indian J Hematol Blood Transfus 32 (Suppl 1), 11–14 (2016). https://doi.org/10.1007/s12288-015-0518-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12288-015-0518-1